Pharmacological CARD9 Inhibition Reduces Pneumocystis murina Burden In Vivo and Ex Vivo

Caspase recruitment domain-containing protein 9 (CARD9) is an important adaptor protein of the innate immune responses to various fungal pathogens, including Pneumocystis species. CARD9 signaling is paramount in Pneumocystis pneumonia (PCP) host defense, and excessive inflammatory responses driven by this molecule can promote deleterious lung injury. We previously demonstrated that BRD5529, a first generation small-molecule CARD9 inhibitor, attenuates pulmonary inflammatory cytokine production during PCP. Here, we investigated the previously unreported effects of BRD5529 on Pneumocystis murina burden in vivo and in an ex vivo PCP-infected precision-cut lung slice (PCLS) model. In vitro, BRD5529 treatment (1 mg/kg) reduced lung organism burden in mice with established PCP, with an effect similar in magnitude to standard-of-care trimethoprim-sulfamethoxazole (TMP-SMX) therapy. In infected PCLS cultured with BRD5529 for 72 h, P. murina viability was also reduced, with the greatest reduction observed at lower BRD5529 concentrations. BRD5529 treatment did not reduce PCLS metabolic activity and viability after 72 h, as assessed by resazurin reduction. Together, these findings suggest that pharmacological CARD9 inhibition may impact organism burden/viability in addition to reducing lung inflammation during PCP.

Authors

Institutions

Publication Details

Journal
bioRxiv (Cold Spring Harbor Laboratory)
Published
2026-11-20
DOI
https://doi.org/10.64898/2026.11.19.767846
Primary Topic
Pneumocystis jirovecii pneumonia detection and treatment
Type
preprint

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
preprint

Pharmacological CARD9 Inhibition Reduces Pneumocystis murina Burden In Vivo and Ex Vivo

Theodore J. Kottom, ANDREW HAR LIMPER, Jenna Lillie McLean
1 links
bioRxiv (Cold Spring Harbor Laboratory)
Pneumocystis jirovecii pneumonia detection and treatment
preprint

Pharmacological CARD9 Inhibition Reduces Pneumocystis murina Burden In Vivo and Ex Vivo

Theodore J. Kottom, ANDREW HAR LIMPER, Jenna Lillie McLean
preprint en

Abstract

Caspase recruitment domain-containing protein 9 (CARD9) is an important adaptor protein of the innate immune responses to various fungal pathogens, including Pneumocystis species. CARD9 signaling is paramount in Pneumocystis pneumonia (PCP) host defense, and excessive inflammatory responses driven by this molecule can promote deleterious lung injury. We previously demonstrated that BRD5529, a first generation small-molecule CARD9 inhibitor, attenuates pulmonary inflammatory cytokine production during PCP. Here, we investigated the previously unreported effects of BRD5529 on Pneumocystis murina burden in vivo and in an ex vivo PCP-infected precision-cut lung slice (PCLS) model. In vitro, BRD5529 treatment (1 mg/kg) reduced lung organism burden in mice with established PCP, with an effect similar in magnitude to standard-of-care trimethoprim-sulfamethoxazole (TMP-SMX) therapy. In infected PCLS cultured with BRD5529 for 72 h, P. murina viability was also reduced, with the greatest reduction observed at lower BRD5529 concentrations. BRD5529 treatment did not reduce PCLS metabolic activity and viability after 72 h, as assessed by resazurin reduction. Together, these findings suggest that pharmacological CARD9 inhibition may impact organism burden/viability in addition to reducing lung inflammation during PCP.

bioRxiv (Cold Spring Harbor Laboratory)
Mayo Clinic (US)
National Institutes of Health
Good health and well-being
Pneumocystis jirovecii pneumonia detection and treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon